Trial Profile
Consequence and management of atrial fibrillation in chronic lymphocytic lymphoma patients treated with ibrutinib or ibrutinib plus rituximab: An international retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2017
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 06 Dec 2016 Results (n=56) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 19 Sep 2016 New trial record